A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

Sponsor
Johnson & Johnson Private Limited
Study ID
NCT03604224
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Canagliflozin 300 mg — DRUG
    Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.

Study Details

The purpose of this study is to observe clinical effectiveness of canagliflozin by mean haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2 diabetes participants.

Key Dates

Start date
Sep 5, 2018
Status verified
Aug 2020
Primary completion
Jul 1, 2019
Completion
Jul 1, 2019

Study Design

Enrollment
178 participants (actual)

Arms

  • Arm: Canagliflozin Containing Treatment Regimens
    No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.

Primary Outcome Measure

Change From Baseline in Mean Hemoglobin A1c (HbA1c) [ Time Frame: Baseline up to 12 weeks ]

Related Studies